Compare NUVB & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | USAS |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2020 | 2004 |
| Metric | NUVB | USAS |
|---|---|---|
| Price | $4.97 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $13.00 | $7.89 |
| AVG Volume (30 Days) | ★ 4.3M | 3.3M |
| Earning Date | 11-02-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,902,000.00 | N/A |
| Revenue This Year | $214.00 | $101.61 |
| Revenue Next Year | $44.13 | $64.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 698.96 | N/A |
| 52 Week Low | $3.36 | $3.52 |
| 52 Week High | $9.75 | $10.50 |
| Indicator | NUVB | USAS |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 40.69 |
| Support Level | $4.10 | $3.57 |
| Resistance Level | $5.16 | $5.25 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 8.16 | 15.72 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.